Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

893.04 -10.21 (-1.13%)
Streaming Delayed Price Updated: 3:47 PM EDT, Oct 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,218,088
Open 898.33
Bid (Size) 892.92 (10)
Ask (Size) 893.24 (20)
Prev. Close 903.25
Today's Range 888.28 - 900.00
52wk Range 547.61 - 972.53
Shares Outstanding N/A
Dividend Yield 0.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss. 
Via Investor's Business Daily
Exposures Product Safety
Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: 'Wait For A Pullback'
On CNBC's "Mad Money Lightning Round," Jim Cramer said no to Nextracker. "Nextracker's a mistake that I made," he added. 
Via Benzinga

Performance

YTD
+50.80%
+50.80%
1 Month
-2.77%
-2.77%
3 Month
+3.86%
+3.86%
6 Month
+21.97%
+21.97%
1 Year
+50.74%
+50.74%

More News

Read More
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
Eli Lilly Alzheimer's Drug Faces Tough Road In UK, Price Watchdog NICE Says Donanemab Is Not Cost-Effective
Via Benzinga
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Exploring NYSE:LLY's high growth characteristics.
Via Chartmill
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Via The Motley Fool
Topics ETFs
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Via The Motley Fool
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Via MarketBeat
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Via The Motley Fool
Investing $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million
Via The Motley Fool
AskSlim Market Week - Friday, Oct. 19
Via Talk Markets
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
Via The Motley Fool
This is Huge News For Eli Lilly Investors
Via The Motley Fool
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Via Investor's Business Daily
Exposures Product Safety
This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.